A new paper from Shoukhrat Mitalipov’s lab on stem cell mitochondria points to a pattern whereby induced pluripotent stem (IPS) cells tend to have more problems if they are from older patients. What does this paper mean for the stem cell field and could it impact more specifically the clinical applications of IPS cells? The new […]
New Mitalipov paper on stem cell mitochondria: challenge for IPS cell field? Read More »
Over the years some scientists including yours truly have expressed concerns about the possibility that mutations could crop up during the reprogramming process to make induced pluripotent stem cells (IPS cells or IPSC). How concerned should we be about IPS cell mutations? A cool new paper, Bhutani, et al, in Nature Communications from a team led by
For IPS cell mutations, some reassuring new data but validation still key Read More »
It’s been a great couple days so far here at the World Stem Cell Summit in Atlanta. You can follow it on Twitter using the #WSCS15 hash tag. I first attended it 5 years ago in Pasadena. One of the special aspects of WSCS is it brings together diverse stakeholders in a way that just
World Stem Cell Summit 2015: IPS cells, #CRISPR, CAR-T Read More »
What’s better for stem cell trials such as for vision loss or Parkinson’s Disease: allogeneic or autologous cells? In a major shift earlier this year, the induced pluripotent stem (IPS) cell trial in Japan for treatment of macular degeneration (MD) switched gears from using the patients’ own cells (called “autologous”) to using banked cells from
Parkinson’s IPS cell trial in Japan switching to allogeneic Read More »
Can cells produced from autologous induced pluripotent stem cell (IPSC or IPS cell) cultures sometimes be immunogenic in patients? This key question has remained somewhat unsettled due to varied findings over the years (e.g. see here), but many of us had generally felt in the last couple years that IPS cell derivative immunogenicity in an
IPS Cell Immunogenicity, Clinical Insights, & Possible Solutions Read More »
As many of you know, the pioneering, first of its kind IPS cell clinical study in Japan has been suspended as I first blogged about here.2020 Update: I believe a version of this study is ongoing. In the comments section of that blog post there has been a helpful overall discussion that has involved Dr.
Historic turning point for IPS cell field in Japan? Read More »
A cool new paper is out in Stem Cell Reports describing long-term tumorigenicity of human induced pluripotent stem cells (IPSC or IPS cells). See graphical abstract. The potential tumorigenicity of IPSC is a major concern when teams around the world are translating IPSC technology to the bedside. Past studies including one from my own lab have
Lessons from New IPS Cell Study Showing Tumors Read More »
In a major first for the stem cell and regenerative medicine fields, a patient in Japan today received a pioneering transplant of a retinal pigmented epithelial (RPE) sheet made from induced pluripotent stem (iPS) cells, also known by the acronym IPSC. This is the first ever iPS cell-based transplant into a human. The patient is
Landmark: patient receives first ever iPS cell based transplant Read More »
A new patent dispute has exploded in the stem cell field related to induced pluripotent stem (iPS) cells. What’s going on? In 2006, Shinya Yamanaka reported cellular reprogramming to create mouse induced pluripotent stem (iPS) cells in Cell and the next year multiple groups along with Yamanaka’s reported creating human iPS cells. It’s no exaggeration
Challenge tries to cancel Yamanaka iPS cell patent Read More »
Just how good are human embryonic stem (ES) cells made by therapeutic cloning via nuclear transfer, with the successful technique first reported by the lab of Shoukhrat Mitalipov at OHSU last year? How do they compare to induced pluripotent stem (iPS) cells or traditional ES cells made from IVF embryos? A new paper in Nature directly tackles these
Review of Mitalipov Nature paper: cloned ES cells vs iPS cells Read More »